Sironax, an emerging biotechnology company, announced on August 2 its completion of round-B financing, bringing the firm’s total fundraising to more than $300 million.
It raised a total of $200 million in this round, which was jointly led by YF Capital and Gaorong Capital. Existing investors included Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, and K2VC also participated. The new investors included MSA Capital, a wholly-owned subsidiary of Abu Dhabi Investment Authority (ADIA), CBC Group, Long River Investments, LSV Capital, Superstring Capital, and Future Innovation Fund.
Since its establishment in 2017, Sironax has built a diverse R&D pipeline that focuses on key pathogenic mechanisms of aging-related degenerative diseases, including cellular programmed death, neuroprotective pathways and neuroinflammation. The company currently undertakes several preclinical studies and has early clinical studies underway for two drug candidates: SIR0365 and SIR2446.
The proceeds from the recently concluded round will be used for the clinical development of receptor-interacting protein kinase 1 (RIPK1) inhibitors and to further expand its R&D scale and pipeline to develop drug candidates for aging-related degenerative diseases.
SEE ALSO: Chip Firm YTMicro Bags Several Hundred Million Yuan in Round-A+ Financing
Dr. Ren Gang, CEO of Sironax, said: “We are very pleased to secure the support of top investors to make our vision of bringing transformative therapies to patients affected by degenerative diseases around the world a reality.”
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: https://pandaily.com/sironax-closes-200m-series-b-financing/
- 1
- 2017
- a
- abu dhabi
- and
- announced
- around
- AUGUST
- August 2
- authority
- bags
- biotechnology
- Bringing
- built
- candidates
- capital
- ceo
- Clinical
- Closes
- company
- completion
- concluded
- Currently
- Death
- develop
- Development
- Dhabi
- diseases
- diverse
- drug
- Early
- emerging
- establishment
- existing
- Expand
- financing
- Firm
- focuses
- from
- fund
- Fundraising
- further
- future
- Gang
- Group
- HTTPS
- in
- included
- Including
- Innovation
- investment
- Investments
- Investors
- Key
- Led
- Long
- make
- million
- more
- New
- participated
- partners
- patients
- pipeline
- plato
- Plato Data Intelligence
- PlatoData
- pleased
- proceeds
- programmed
- Protein
- R&D
- raised
- Reality
- recently
- ren
- River
- roads
- round
- Said
- Scale
- secure
- Series
- Series B
- several
- studies
- subsidiary
- support
- Temasek
- The
- the world
- to
- top
- Total
- transformative
- Underway
- venture
- vision
- which
- will
- world
- Yuan
- zephyrnet